We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
SeraNovo and Carna Biosciences Enter Second License Agreement for Development of Oral Formulation of Kinase Inhibitor
Product News

SeraNovo and Carna Biosciences Enter Second License Agreement for Development of Oral Formulation of Kinase Inhibitor

SeraNovo and Carna Biosciences Enter Second License Agreement for Development of Oral Formulation of Kinase Inhibitor
Product News

SeraNovo and Carna Biosciences Enter Second License Agreement for Development of Oral Formulation of Kinase Inhibitor

Credit: Unsplash

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "SeraNovo and Carna Biosciences Enter Second License Agreement for Development of Oral Formulation of Kinase Inhibitor"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

SeraNovo B.V. has announced that it has signed a second License Agreement with Carna Biosciences, Inc., a company engaged in the drug development of kinase inhibitors. Under the agreement, the companies will expand their existing collaboration and jointly develop an oral formulation of a new active ingredient with an enhanced bioavailability. Utilizing its proprietary Deep Eutectic Solvent (DES) formulation platform, SeraNovo is formulating one of Carna’s proprietary drugs to increase its oral bioavailability. The DES formulation platform is based on GRAS excipients that are used for oral administration and broadly used in the industry.

Advertisement